Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.

Questions Answered

  • What is the physician perspective on steroids and antihistamines for chronic urticaria? How frequently are these therapies prescribed?
  • How do allergists and dermatologists diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are inducible and spontaneous urticaria treated similarly, or is the treatment algorithm distinct?
  • Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
  • How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform, and how will emerging biologics compare? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 18 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other DRG research.

Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients

Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2029, segmented by brands/generics.

Emerging therapies: Phase III / PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Urticaria - Landscape & Forecast - Disease Landscape And Forecast
    • Key Updates
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Chronic Urticaria: 2019
          • Market Share of Drug Classes for Chronic Urticaria: 2029
          • Chronic Urticaria SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Chronic Urticaria?
          • What Factors Are Constraining the Market for Chronic Urticaria?
          • Major-Market Sales of Select Therapies in Chronic Urticaria: 2019-2029
          • Major-Market Patient Share of Select Therapies in Chronic Urticaria: 2019-2029
        • Segment-Specific Trends
          • Major-Market Sales of Omalizumab in Chronic Urticaria: 2019-2029
          • Major-Market Patient Share of Ligelizumab in Chronic Spontaneous Urticaria: 2023-2029
          • Major-Market Patient Share of Ligelizumab in Chronic Inducible Urticaria: 2023-2029
          • Major-Market Sales of Dupilumab in Chronic Urticaria: 2023-2029
          • Major-Market Patient Share of Dupilumab in Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: 2023-2029
          • Major-Market Sales of Remibrutinib: 2024-2029
          • Major-Market Patient Share of Montelukast in Chronic Urticaria: 2019-2029
          • Major-Market Sales of Antihistamines in Chronic Urticaria: 2019-2029
          • Major-Market Sales of TNF-Alpha Inhibitors in Chronic Urticaria: 2019-2029
          • Major-Market Sales of Therapies Used Off-Label in Chronic Urticaria: 2019-2029
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Pathophysiology
              • Differential Diagnosis
              • Forms of Chronic Inducible Urticaria
            • Key Pathways and Drug Targets
              • Cell Types Involved in Chronic Urticaria
              • Key Drug Targets & Pathways
          • Epidemiology
            • Key Findings
              • Key Updates
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed 12-Month Prevalence of Chronic Urticaria
              • Diagnosed Prevalent Cases of Chronic Urticaria: 2019 -2029 (thousands)
              • Disease Definition
              • Methods
              • Sources Used for Total 12-Month Prevalence of Chronic Spontaneous Urticaria
              • Total Prevalent Cases of Chronic Spontaneous Urticaria: 2019-2029 (thousands)
              • Disease Definition
              • Methods
              • Sources Used for Total 12-Month Prevalence of Chronic Inducible Urticaria
              • Total 12-Month Prevalent Cases of Chronic Inducible Urticaria: 2019-2029 (thousands)
              • Diagnosed Prevalent Cases of Chronic Spontaneous Urticaria: 2019-2029 (thousands)
              • Diagnosed Prevalent Cases of Chronic Inducible Urticaria: 2019-2029 (thousands)
              • Drug-Treated Prevalent Cases of Chronic Spontaneous Urticaria: 2019-2029
              • Drug-Treated Prevalent Cases of Chronic Inducible Urticaria: 2019-2029
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Chronic Urticaria
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Chronic Urticaria
                • Current Treatments Used for Chronic Urticaria
                • Market Events Impacting the Use of Key Current Therapies for Chronic Urticaria
                • Advantages and Disadvantages of Second-Generation H1 Antihistamines
                • Expert Insight: Second-Generation H1 Antihistamines
                • Advantages and Disadvantages of First-Generation H1 Antihistamines
                • Expert Insight: First-Generation H1 Antihistamines
                • Advantages and Disadvantages of Xolair
                • Expert Insight: Xolair
                • Advantages and Disadvantages of Montelukast
                • Expert Insight: Montelukast
                • Advantages and Disadvantages of Immunosuppressants
                • Expert Insight: Immunosuppressants
                • Advantages and Disadvantages of TNF-α Inhibitors
                • Expert Insight: TNF-α Inhibitors
                • Advantages and Disadvantages of Off-Label Therapies
              • Medical Practice
                • Overview
                • Country-Specific Urticaria Treatment Guidelines
                • Factors Influencing Drug Selection in Chronic Urticaria
                • Treatment Decision Tree for Chronic Urticaria: United States
                • Treatment Decision Tree for Chronic Urticaria: Europe
                • Treatment Decision Tree for Chronic Urticaria: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Chronic Urticaria
              • Top Unmet Needs in Chronic Urticaria: Current and Future Attainment
              • Expert Insight: Unmet Need in Chronic Urticaria
            • Emerging Therapies
              • Key Findings
                • Pipeline Trends in Chronic Urticaria
              • Key Emerging Therapies
                • Key Therapies in Development for Chronic Urticaria
                • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Chronic Urticaria
                • Ligelizumab Profile
                • Key Ongoing Clinical Trials of Ligelizumab in the Treatment of Chronic Urticaria
                • Analysis of the Clinical Development Program for Ligelizumab
                • Expert Insight: Ligelizumab
                • Expectations for Launch and Sales Opportunity of Ligelizumab in Chronic Urticaria
                • Dupilumab Profile
                • Key Ongoing Clinical Trials of Dupilumab in the Treatment of Chronic Urticaria
                • Analysis of the Clinical Development Program for Dupilumab
                • Expert Insight: Dupilumab
                • Expectations for Launch and Sales Opportunity of Dupilumab in Chronic Urticaria
                • Remibrutinib Profile
                • Key Ongoing Clinical Trials of Remibrutinib in the Treatment of Chronic Urticaria
                • Analysis of the Clinical Development Program for Remibrutinib
                • Expert Insight: Remibrutinib
                • Expectations for Launch and Sales Opportunity of Remibrutinib in Chronic Urticaria
                • Fenebrutinib Profile
                • Analysis of the Clinical Development Program for Fenebrutinib
                • Expert Insight: Fenebrutinib
                • Expectations for Launch and Sales Opportunity of Fenebrutinib in Chronic Urticaria
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for Chronic Urticaria
            • Access & Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Access Considerations in Chronic Urticaria: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Chronic Urticaria: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Chronic Urticaria: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Key Abbreviations Related to Chronic Urticaria
              • Chronic Urticaria Bibliography

          Author(s): Kristine Mackin, Ph.D.; Devashri Mukherjee, M.P.H.

          Kristine Mackin, Ph.D., is a principal analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. Her expertise includes emerging microbiome-based therapies, psoriatic arthritis, chronic obstructive pulmonary disease, and asthma. Prior to joining DRG, Dr. Mackin was involved with a new company pitch focusing on the infant microbiome, now realized as Commense, during an internship at Puretech Ventures in Boston. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins.


          Related Reports

          Urticaria - Unmet Need - Detailed, Expanded Analysis (US & EU) Chronic Inducible Urticaria And Chronic Spontaneous Urticaria

          The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticar...

          View Details

          Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Inducible Urticaria | US | 2020

          Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic spontaneous urticaria (CSU) to standa...

          View Details

          Urticaria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US)

          MARKET OUTLOOKChronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic...

          View Details

          Urticaria - Epidemiology - Mature Markets

          DRG Epidemiology's coverage of urticaria comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy...

          View Details